" /> Septooptic dysplasia - CISMeF





Preferred Label : Septooptic dysplasia;

CISMeF acronym : CPHD5;

Type : Phenotype, molecular basis known;

Alternative titles and symbols : De morsier syndrome;

Included titles and symbols : Pituitary hormone deficiency, combined, 5; Growth hormone deficiency with pituitary anomalies; CPHD5;

Description : Septooptic dysplasia is a clinically heterogeneous disorder loosely defined by any combination of optic nerve hypoplasia, pituitary gland hypoplasia, and midline abnormalities of the brain, including absence of the corpus callosum and septum pellucidum (Dattani et al., 1998). The diagnosis of this rare congenital anomaly is made when 2 or more features of the classic triad are present. Approximately 30% of patients have complete manifestations, 62% display hypopituitarism, and 60% have an absent septum pellucidum. The disorder is equally prevalent in males and females and is more common in infants born to younger mothers, with a reported incidence of 1 in 10,000 live births (summary by Webb and Dattani, 2010). Also see 516020.0012 for a form of septooptic dysplasia associated with cardiomyopathy and exercise intolerance.;

Inheritance : Autosomal dominant; Autosomal recessive;

Molecular basis : Caused by mutation in the homeo box gene expressed in ES cells (HESX1, 601802.0001);

Laboratory abnormalities : Low or absent growth hormone (GH); Low or absent adrenocorticotropic hormone (ACTH); Low or absent follicle-stimulating hormone (FSH); Low or absent thyrotropin (TSH); Low or absent luteinizing hormone (LH);

Prefixed ID : #182230;

Details


You can consult :


Nous contacter.
07/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.